Articles

tryton stent, bifurcation stenting

clinical trial designed to measure the effectiveness of using a dedicated side branch-covering bare metal...

Absorb, Abbott

The interventional cardiology market includes, but is not limited to, drug-eluting stents, bare-metal stents, percutaneous transluminal coronary angioplasty (PTCA) and cutting balloon catheters....

Tryton Side Branch Stent TRYTON Pivotal FDA IDE trial

Tryton Medical Inc. announced the completion of enrollment in the TRYTON Pivotal U.S. Food and Drug Administration (FDA) IDE trial evaluating the Tryton Side Branch...

November 1, 2012 — InspireMD Inc. announced that its proprietary MGuard embolic protection stent (EPS) was shown to be significantly superior when compared to standard bare metal and drug-eluting...

April 15, 2012, will mark the 10th anniversary of the approval of the first drug-eluting stent (DES). Ten years ago, the mood surrounding the new anti-restinotic silver bullet stent was one of...

There have been several key news items from the U.S. stent market over the past year. These include the introduction of several new stents, Cordis pulling out of the market, an expanded indication...

April 8, 2011 – In the largest randomized, multicenter trial to compare drug-eluting stents (DES) and bare-metal stents (BMS) placed in saphenous vein graft lesions, researchers found that DES led...

In the world of endovascular devices, the rule is no longer one size fits all. The recent increase in the variety of stents for percutaneous coronary intervention (PCI) offers the physician of a...

There is no consensus about whether atherosclerotic renal artery stenosis should be stented or treated medically. There are strong opinions on both sides and clinical data up to now is heavily...